About: SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector
Creator	Kapadia, S Kapadia, Sagar Lamirande, J Roberts, K Rose, John Simon, Ian Subbarao, L Vogel, E
Source	Elsevier; Medline; PMC
abstract	Abstract A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-CoV S protein provides long-term protection of immunized mice from SARS-CoV infection (Kapadia, S.U., Rose, J. K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A., 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340(2), 174–82.). Because it is difficult to obtain regulatory approval of vaccine based on live viruses, we constructed a replication-defective single-cycle VSV vector in which we replaced the VSV glycoprotein (G) gene with the SARS-CoV S gene. The virus was only able to infect cells when pseudotyped with the VSV G protein. We measured the effectiveness of immunization with the single-cycle vaccine in mice. We found that the vaccine given intramuscularly induced a neutralizing antibody response to SARS-CoV that was approximately ten-fold greater than that required for the protection from SARS-CoV infection, and significantly greater than that generated by the replication-competent vector expressing SARS-CoV S protein given by the same route. Our results, along with earlier studies showing potent induction of T-cell responses by single-cycle vectors, indicate that these vectors are excellent alternatives to live-attenuated VSV.
has issue date	2008-06-20(xsd:dateTime)
bibo:doi	10.1016/j.virol.2008.03.002
bibo:pmid	18396306
has license	els-covid
sha1sum (hex)	c75b2dcbddee584a18274cd1f49782e4e9f2a010
schema:url	https://doi.org/10.1016/j.virol.2008.03.002
resource representing a document's title	SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector
has PubMed Central identifier	PMC7103385
has PubMed identifier	18396306
schema:publication	Virology
resource representing a document's body	covid:c75b2dcbddee584a18274cd1f49782e4e9f2a010#body_text
is schema:about of	named entity 'vectors' named entity 'response' named entity 'potent' named entity 'expressing' named entity 'SARS' named entity 'LONG-TERM' named entity 'CONSTRUCTED' named entity 'MEASURED' named entity 'REQUIRED' named entity 'TO INFECT' named entity 'GLYCOPROTEIN' covid:arg/c75b2dcbddee584a18274cd1f49782e4e9f2a010 named entity 'ATTENUATED' named entity 'ATTENUATED' named entity 'REGULATORY' named entity 'G PROTEIN' named entity 'PROTEIN ' named entity 'S PROTEIN' named entity 'LIVE' named entity 'SARS-COV INFECTION' named entity 'REPLICATION' named entity 'SARS-COV INFECTION' named entity 'PROTECTION' named entity 'CELLS' named entity 'IMMUNIZED' named entity 'MICE' named entity 'PROTEIN ' named entity 'DEFECTIVE' named entity 'BASED' named entity 'EXCELLENT' named entity 'VIROLOGY' named entity 'ROUTE' named entity 'CORONAVIRUS INFECTION' named entity 'APPROXIMATELY' named entity 'VIRUSES' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'RECOMBINANT' named entity 'LIVE' named entity 'PROTECTION' named entity 'VIRUS' named entity 'FOLD' named entity 'STUDIES' named entity 'GENERATED' named entity 'T-CELL' named entity '28G' named entity 'THESE' named entity 'COMPETENT' named entity 'LONG-TERM' named entity 'VACCINE' named entity 'EARLIER' named entity 'GENE' named entity 'FOUND' named entity 'VECTORS' named entity 'ANTIBODY RESPONSE' named entity 'CYCLE' named entity 'SARS CORONAVIRUS' named entity 'EFFECTIVENESS' named entity '174' named entity 'SARS VACCINE' named entity 'VSV' named entity 'INDUCED' named entity 'GIVEN' named entity 'RESULTS' named entity 'IMMUNIZATION' named entity 'GREATER THAN' named entity 'INDUCTION' named entity 'MICE' named entity 'RESPONSES' named entity '282' named entity 'APPROVAL' named entity 'REPLACED' named entity '340' named entity 'DIFFICULT' named entity 'SINGLE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software